Zydus Lifesciences Announcements
Certificate under Reg 74(5) of SEBI (Depositories and Participants) Regulations, 2018
14 Oct, 2025 | 10:26am • Source: BSE
Newspaper publication of notice of loss of share certificate of the Company, published in Financial Express English and Gujarati editions, both on October 9, 2025.
09 Oct, 2025 | 01:45pm • Source: BSE
Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg.
06 Oct, 2025 | 04:25pm • Source: BSE
Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL.
06 Oct, 2025 | 03:04pm • Source: BSE
Newspaper publication of notice of loss of share certificate of the Company published in the Financial Express English and Gujarati editions, both on October 4,...
04 Oct, 2025 | 11:49am • Source: BSE
Sentynl Therapeutics updates on its NDA for CUTX-101
01 Oct, 2025 | 05:52pm • Source: BSE
Update on acquisition of API business
30 Sep, 2025 | 04:34pm • Source: BSE
Receipt of order from Commissioner of CGST, Ahmedabad
25 Sep, 2025 | 03:49pm • Source: BSE
Zydus Lifesciences Limited has informed the Exchange about General UpdatesZydus Lifesciences Limited
24 Sep, 2025 | 10:40am • Source: NSE
Transcript of the 30th Annual General Meeting
24 Sep, 2025 | 10:34am • Source: BSE
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 23, 2025, titled "Press Release
23 Sep, 2025 | 05:04pm • Source: NSE
Press Release
23 Sep, 2025 | 12:15pm • Source: BSE
Press Release
21 Sep, 2025 | 08:46am • Source: BSE
The Company is going to participate in 10th Annual J. P. Morgan India Conference at Mumbai on September 23, 2025.
16 Sep, 2025 | 06:25pm • Source: BSE
Press Releases
15 Sep, 2025 | 06:56pm • Source: BSE
Closure of USFDA inspection at Zydus'' injectable manufacturing plant at Jarod.
05 Sep, 2025 | 07:31pm • Source: BSE
Zydus Lifesciences Limited has informed the Exchange about change in Management
05 Sep, 2025 | 10:09am • Source: NSE
Appointment of Senior Management
05 Sep, 2025 | 09:45am • Source: BSE
Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA) for the US market.
04 Sep, 2025 | 03:52pm • Source: BSE